- Home
- ISRG vs NVS Comparison
ISRG vs NVS Comparison
Compare ISRG & NVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ISRG | NVS |
|---|---|---|
| Founded | 1995 | 1895 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 132.0B | 261.7B |
| IPO Year | 1998 | 2001 |
Fundamental Metrics
Financial Performance| Metric | ISRG | NVS |
|---|---|---|
| Price | $393.82 | $140.34 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 19 | 5 |
| Target Price | ★ $591.32 | $144.00 |
| AVG Volume (30 Days) | 2.1M | ★ 2.2M |
| Earning Date | 04-21-2026 | 04-28-2026 |
| Dividend Yield | N/A | ★ 2.16% |
| EPS Growth | ★ 22.59 | N/A |
| EPS | ★ 4.57 | N/A |
| Revenue | ★ $10,064,700,000.00 | N/A |
| Revenue This Year | $16.64 | $2.30 |
| Revenue Next Year | $13.91 | $5.27 |
| P/E Ratio | $83.93 | ★ $23.13 |
| Revenue Growth | ★ 20.51 | N/A |
| 52 Week Low | $328.57 | $121.57 |
| 52 Week High | $603.88 | $170.46 |
Technical Indicators
Market Signals| Indicator | ISRG | NVS |
|---|---|---|
| Relative Strength Index (RSI) | 60.55 | 37.70 |
| Support Level | $345.25 | $136.28 |
| Resistance Level | $405.34 | $157.70 |
| Average True Range (ATR) | 11.25 | 2.28 |
| MACD | 3.05 | -1.16 |
| Stochastic Oscillator | 95.96 | 12.48 |
Price Performance
Historical ComparisonAbout ISRG Intuitive Surgical Inc.
Intuitive develops, produces, and markets a robotic system for assisting minimally invasive surgery. It also provides the instrumentation, disposable accessories, and warranty services for the system. The company has placed more than 10,000 da Vinci systems in hospitals worldwide, with more than 6,000 installations in the US and a growing number in emerging markets.
About NVS Novartis AG
Novartis develops and manufactures innovative drugs. Key areas of drug development are oncology, immunology, neuroscience, and cardiovascular, renal, and metabolic. It also has an established medicines business, which includes off-patent franchises. The company sells its products globally, with the United States constituting close to one-third of total revenue.